Amgen Inc (AMGN) Financial Statements
Historical financial data — 40 statements covering FY2016–FY2025
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla f...
Amgen Inc's revenue increased 10.0% year over year, from $33.42B to $36.75B.
Net income increased 88.5% over the same period, from $4.09B to $7.71B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 60% in total.
Total debt decreased by 11.6% to $50.01B.
The debt-to-equity ratio stands at 5.78, indicating a high leverage profile.
Operating cash flow declined 13.3% to $9.96B.
Amgen Inc maintains a strong net profit margin of 21.0%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2023 | $13.09B+114.4% | $4.22B | $9.56B | $4.61B | $5.17B | $90.27B | $59.38B | $6.78B |
| Q3 FY2023 | $19.99B+52.7% | $5.95B | $14.65B | $6.63B | $7.93B | $90.53B | $59.04B | $7.66B |
| Q1 FY2024 | $7.45B-62.8% | $-113.0M | $4.25B | $991.0M | $689.0M | $92.98B | $60.06B | $5.02B |
| Q3 FY2024 | $24.34B+226.8% | $3.46B | $14.59B | $4.95B | $6.72B | $90.88B | $56.85B | $7.53B |
| Q1 FY2025 | $8.15B-66.5% | $1.73B | $5.18B | $1.18B | $1.39B | $89.37B | $54.01B | $6.21B |
| Q2 FY2025 | $17.33B+112.6% | $3.16B | $11.35B | $3.83B | $3.67B | $87.90B | $53.76B | $7.43B |
| Q3 FY2025 | $26.89B+55.2% | $6.38B | $17.82B | $6.36B | $8.36B | $90.14B | $52.43B | $9.62B |
| Q1 FY2026 | $8.62B-67.9% | $1.82B | $5.87B | $2.67B | $2.19B | $92.50B | $51.89B | $9.19B |
Balance Sheet Summary (Latest Period)
Total Assets
$90.59B
Total Liabilities
$81.93B
Total Equity
$8.66B
Cash & Equivalents
$9.13B
Total Debt
$50.01B
Current Assets
$29.06B
Current Liabilities
$25.49B
Retained Earnings
$-25.11B